NECLIFE

Nectar Lifesciences Share PriceNectar Lifesciences

₹17.3
0.3 (1.76%)
As on 04 June, 2023 | 16:30 BSE: 532649 NSE: NECLIFE

Nectar Lifesciences Performance

Day Range

  • Low
  • High
17.3

52 Week Range

  • Low
  • High
17.3
  • Open Price
  • Previous Close
  • Volume

Start SIP in Nectar Lifesciences

Start SIP

Nectar Lifesciences Share Price

  • Over 1 Month -3.62%
  • Over 3 Month -0.86%
  • Over 6 Month -18.4%
  • Over 1 Year -33.2%

Nectar Lifesciences Key Statistics

P/E Ratio -16
PEG Ratio 0.1
Market Cap Cr 388
Price to Book Ratio 0.4
EPS -1
Dividend 0
Relative Strength Index 53.47
Money Flow Index 66.65
MACD Signal -0.1
Average True Range 0.54

Nectar Lifesciences Investment Rating

  • Master Rating:
  • Nectar Lifesciences has an operating revenue of Rs. 1,524.61 Cr. on a trailing 12-month basis. An annual revenue de-growth of -7% needs improvement, Pre-tax margin of -3% needs improvement, ROE of -2% is poor and needs improvement. The company has a reasonable debt to equity of 21%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 12 which is a POOR score indicating inconsistency in earnings, a RS Rating of 16 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 104 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Nectar Lifesciences Financials
IndicatorMar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 389344389403476
Operating Expenses Qtr Cr 369343396361427
Operating Profit Qtr Cr 201-74249
Depreciation Qtr Cr 1515151514
Interest Qtr Cr 2017212117
Tax Qtr Cr -2-8-1026
Net Profit Qtr Cr 5-9-22412

Nectar Lifesciences Technicals

EMA & SMA

Current Price
₹17.3
0.3 (1.76%)
  • Bullish Moving Average
  • ___
  • 10
  • Bearish Moving Average
  • ___
  • 6
  • 20 Day
  • ₹17.08
  • 50 Day
  • ₹17.35
  • 100 Day
  • ₹18.27
  • 200 Day
  • ₹20.07
  • 20 Day
  • ₹17.06
  • 50 Day
  • ₹17.01
  • 100 Day
  • ₹18.2
  • 200 Day
  • ₹20.32

Nectar Lifesciences Resistance and Support

PIVOT
₹16.99
Resistance
First Resistance ₹17.22
Second Resistance ₹17.44
Third Resistance ₹17.67
RSI 53.47
MFI 66.66
MACD Single Line -0.1
MACD -0.08
Support
First Resistance ₹16.77
Second Resistance ₹16.54
Third Resistance ₹16.32

Nectar Lifesciences Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 268,460 16,214,984 60.4
Week 170,441 10,845,161 63.63
1 Month 157,371 9,535,103 60.59
6 Month 492,331 21,268,701 43.2

Nectar Lifesciences Result Highlights

Nectar Lifesciences Synopsis

NSE-Medical-Generic Drugs

Nectar Lifesciences is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1524.61 Cr. and Equity Capital is Rs. 22.43 Cr. for the Year ended 31/03/2023. Nectar Lifesciences Ltd. is a Public Limited Listed company incorporated on 27/06/1995 and has its registered office in the State of Punjab, India. Company’s Corporate Identification Number(CIN) is L24232PB1995PLC016664 and registration number is 016664.
Market Cap 388
Sales 1,525
Shares in Float 12.56
No of funds 5
Yield 0.22
Book Value 0.36
U/D Vol ratio 1
LTDebt / Equity 21
Alpha -0.16
Beta 0.62

Nectar Lifesciences

Owner NameMar-23Dec-22Sep-22Jun-22
Promoters 55.8%55.8%55.8%55.8%
Mutual Funds
Foreign Portfolio Investors 1.48%1.4%1.53%1.49%
Individual Investors 24.47%24.53%24.34%24.2%
Others 18.25%18.27%18.33%18.51%

Nectar Lifesciences Management

Name Designation
Mr. Sanjiv Goyal Chairman & Managing Director
Dr. Kuldip Kumar Bhasin Independent Director
Dr. Indu Pal Kaur Independent Director
Mr. Ajay Swaroop Independent Director
Dr. Rupinder Tewari Independent Director
Ms. Meena Verma Nominee Director

Nectar Lifesciences Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Nectar Lifesciences Corporate Action

Date Purpose Remarks
2023-05-26 Audited Results & A.G.M.
2023-02-14 Quarterly Results
2022-11-14 Quarterly Results
2022-08-13 Quarterly Results
2022-05-30 Audited Results

Nectar Lifesciences MF Shareholding

Name Amount(cr)
Motilal Oswal S&P BSE Healthcare ETF 6

Nectar Lifesciences FAQs

What is Share Price of Nectar Lifesciences ?

Nectar Lifesciences share price is ₹17 As on 04 June, 2023 | 16:16

What is the Market Cap of Nectar Lifesciences ?

The Market Cap of Nectar Lifesciences is ₹388 Cr As on 04 June, 2023 | 16:16

What is the P/E ratio of Nectar Lifesciences ?

The P/E ratio of Nectar Lifesciences is -16 As on 04 June, 2023 | 16:16

What is the PB ratio of Nectar Lifesciences ?

The PB ratio of Nectar Lifesciences is 0.4 As on 04 June, 2023 | 16:16

Q2FY23

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number